Verin completed his Ph.D. at the age of 29 years from Moscow State University, Moscow, USSR, and postdoctoral studies at the University of Indiana. During his scientific carrier, he was a faculty member at Johns Hopkins and the University of Chicago. Currently, he is a Professor at the Vascular Biology Center and Pulmonary Division, School of Medicine, Medical College of Georgia, at Augusta University, Augusta, GA.   He has published more than 170 papers in reputed journals primarily in the field of pulmonary vascular endothelial barrier regulation.  He served as an Editorial board member of the American Journal of Physiology (Lung) from 2006-2011 and Editor-in-chief of the academic journal, Vessel Plus, in 2016-2022. He is currently serving as an academic editor of the British Journal of Medicine and Medical Research and Cardiology and Angiology, and an editorial board member in several other journals in the field of pulmonary/cardiovascular research such as Biomolecules, Cardiovascular Pharmacology, Journal of Multidisciplinary Pathology, Tissue Barriers, World Journal of Respirology.

M Lavae-Mokhtari is a consultant in the Respiratory Intensive Care Unit at General Hospital Ibbenburen in Germany since 2013. He has seven publications, 17 national and international poster publications, one book publication, and three scientific international and one national oral presentation. He has 152 citations and a 17.48 RG Score by research gate. He is a member of the German Respiratory Society, Section Intensive-Care and Ventilation Medicine, European Respiratory Society, Section Intensive-Care and Ventilation Medicine, and Section Thorax oncology and German Interdisciplinary Society of Outpatient Ventilation.

Tim Higenbottam is a recognized expert in Respiratory Medicine, including asthma, and has extensive experience in clinical development and regulatory affairs from within the pharmaceutical industry and academia. He was a Professor of Medicine at Sheffield University from 1995 and 2001. At Chiesi Farmaceutici, he was Director of Corporate Clinical Development and achieved market approvals for the NEXThaler® DPI for Asthma and FOSTAIR® for COPD. Professor Higenbottam previously held senior positions with AstraZeneca.

Stanislav Kotlyarov was educated as a medical doctor in 2007 and received his Ph.D. in 2011. His thesis was on "Structure of respiratory symptoms and spirometry screening in the assessment of chronic obstructive pulmonary disease at the primary treatment level". He works at Ryazan State Medical University as head of the department. He is board-certified as a general practitioner and family medicine physician. Was involved in clinical trials of medicines and medical devices. He has over 50 publications, including several articles in leading international peer-reviewed journals. Areas of research interests: molecular immunology, and molecular pharmacology of respiratory and cardiac diseases.

Hamid Mcheick is a full professor in Computer Science department at the University of Québec at Chicoutimi, Canada. He has more than 25 years of experience in both academic and industrial area. He has done his PhD in Software Engineering and Distributed System in the University of Montreal, Canada. He is working on smart and connected software applications; healthcare framework; smart frameworks/systems; software architectural models and frameworks; Intelligent Context-aware Applications; Intelligent Internet of Things architecture; Cloud Computing. He has supervised many post-doctorate, PhD, master and bachelor students. He has nine book chapters, more than 60 research papers in international journals and more than 150 research papers in international/national conference and workshop proceedings in his credit. Dr. Mcheick has given many keynote speeches and tutorials in his research area, particularly in Smart Healthcare systems, Pervasive and Ubiquitous computing, Distributed Middleware Architectures, Software Connectors, Service Oriented Computing, Internet of Things (IoT), Smart Architectural Frameworks, Mobile Edge Computing, Fog Computing, and Cloud Computing. Dr. Mcheick has gotten many grants from governments, industrials and academics. He is a chief in editor, chair, co-chair, reviewer, member in many organizations (such as IEEE, ACM, Springer, MDPI, Elsevier, Inderscience, Wiley) around the world.

Iulia D. Popescu is a Research Assistant Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh, and she has significant experience in transplant research in basic immunology with a focus on mechanisms of CMV-specific lung mucosal/systemic immunity and viral control, as well on EBV, showing the important role for the Type-1 transcription factor T-bet and Eomes as well other immune markers. She also has experience in studying T cell mechanisms of allograft rejection/tolerance in lung transplantation. She is the Co-PI on a U01 award (AI125050) to perform a novel clinical trial to perform tandem lung and bone marrow transplantation in select individuals with primary immunodeficiencies and end-stage lung disease and to perform mechanistic pathogen-specific and alloimmune tolerance studies in these study participants. She is also a Co-PI on an R01 award HL133184-01, “Role of F-box Proteins in Lung Transplantation.” In her study she has focused on viral mucosal immunology, She is the also Co-PI on U01HL121814, “Immune Mechanisms of HIV-associated COPD. In addition, She is the Co-PI in another lung transplant research effort focused on novel drug development for antibody-mediated lung transplant rejection (Amgen). She is the University of Pittsburgh site Co-PI for the R01, “Clinical Risk Factors in Primary Graft Dysfunction” (HL087115). She is proficient in measuring lung mucosal and systemic viral-specific and allospecific multifunctional T cell immunity and phenotyping in lung transplant recipients. She has helped in the establishment of an extensive lung transplant tissue biorepository/registry (BREATHE-LT) that collects and stores BAL fluid/cells, blood for plasma/PBMC, bronchial brushes, along with a clinical research database for phenotyping lung transplant recipients and assessing outcomes for translational studies. She is also working as a Co-PI on a current CFF award, “Molecular and Clinical Endotypes in Chronic Lung Allograft Dysfunction” in which RNA sequence analysis of the airway transcriptome and proteomics in ongoing studies in the mechanisms of CLAD. Finally, they have recently reported on the impact of short telomeres in pulmonary fibrosis lung transplant recipients who demonstrate increased CMV complications and impaired viral immunity. Pertinent to this proposal she also has significant experience assessing alloimmunity, using flow cytometry, in addition to viral immunity, and evaluating the phenotype of T cells, proliferation, and effector multifunction to measure inflammatory responses, which makes me suited to serve as PI on this Stuart K. Patrick grant.

Dr. Manoj Nargund is a trained Pharmacologist {Doctor of Medicine (MD)} from University of Mumbai, India, & also holds a Diploma in Pharmaceutical Business Management. He has earlier served as Resident Medical Officer in internal medicine & ICU in prestigious public hospitals at Mumbai for 3 years; has been on teaching faculty for Pharmacology for medical & pharmacy graduates, & has 5 publications in peer-reviewed journals. As an Asia Pacific Medical Affairs & Clinical R&D professional in pharmaceutical industry for over 21 years, he has led key products in companies like Pfizer, Johnson & Johnson, Novartis, Zydus Cadila, Macleods, Abbott, & GSK, in multiple therapy areas, including in Respiratory & Infectious Diseases, to address unmet therapeutic needs of patients with asthma, COPD, ILD/IPF, PAH, & in various bacterial & fungal respiratory infections. Some of his key achievements in these areas include, introduction of doxofylline, montelukast & deflazacort for asthma/COPD as per GINA/GOLD guidelines; introduction of 3rd/4th generation beta-lactams & fluoroquinolones; & implementation of various digital/non-digital medical education intiatives for physicians & patients. He is passionate about learning & implementing strategies for addressing the challenges of sub-optimal control of asthma & COPD, & increasing anti-microbial resistance (AMR).

Aloys Tan is a medical practitioner by profession with 40+ years of experience in the health care industry in the Netherlands and Asia. His interest lies in bridging the gap between fundamental research and its daily applications, particularly in the Healthcare realm in the European-Asia base. Between 1980 and 2000 he was chairman of the Pulmonology department of St. Joseph Hospital Veldhoven. Ever since, he has held various management positions in the areas of health care, social services and IT. Currently, Dr. Tan is partner and advisor in Landcent Europe Division and is instrumental in guiding Landcent’s regulatory initiatives in the region.